Ligand Pharmaceuticals Inc. is restructuring its Avinza license deal with Elan Corp. plc, eliminating Elan's co-promotion rights in North America and dropping Elan's royalty rate. But to do so, Ligand will pick up $135 million in debt for a product that is not generating revenue as strongly as management had predicted, a scenario that has investors questioning the future. Read More
